GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Pre-Tax Income

Kancera AB (OSTO:KAN) Pre-Tax Income : kr-60.43 Mil (TTM As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Kancera AB's pretax income for the three months ended in Sep. 2023 was kr-10.73 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was kr-60.43 Mil. Kancera AB's pretax margin was %.

During the past 13 years, Kancera AB's highest Pretax Margin was -409.16%. The lowest was -49732.74%. And the median was -5177.20%.


Kancera AB Pre-Tax Income Historical Data

The historical data trend for Kancera AB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Pre-Tax Income Chart

Kancera AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.94 -36.10 -40.50 -45.69 -52.48

Kancera AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.90 -14.01 -17.50 -18.19 -10.73

Competitive Comparison of Kancera AB's Pre-Tax Income

For the Biotechnology subindustry, Kancera AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kancera AB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kancera AB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Kancera AB's Pre-Tax Income falls into.



Kancera AB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Kancera AB's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-51.934+0+-0.118+0+-0.432
=-52.48

Kancera AB's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-10.546+0+-0.237+0.05+-1.7763568394003E-15
=-10.73

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-60.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kancera AB  (OSTO:KAN) Pre-Tax Income Explanation

Kancera AB's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-10.733/0
=%

During the past 13 years, Kancera AB's highest Pretax Margin was -409.16%. The lowest was -49732.74%. And the median was -5177.20%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kancera AB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Kancera AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Kancera AB (OSTO:KAN) Business Description

Traded in Other Exchanges
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB (OSTO:KAN) Headlines

No Headlines